drugset / Trial / NCT02802813
P.Vivax Treatment Trial
Phase 1/2
Completed
41 enrolled
University of Oxford
Mahidol Oxford Tropical Medicine Research Unit · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This study aims to determine whether a 14 day course of 0.5 mg/kg/day primaquine can eliminate subclinical P. vivax infections detected by high volume ultra-sensitive PCR (uPCR).
Timeline
- Start
- 2016-06-14
- Primary completion
- 2018-06-15
- Completion
- 2018-06-15
Publications
- Phommasone K, van Leth F, Imwong M, Henriques G, Pongvongsa T, Adhikari B, Peto TJ, Promnarate C, Dhorda M, Sirithiranont P, Mukaka M, Peerawaranun P, Day NPJ, Cobelens F, Dondorp AM, Newton PN, White NJ, von Seidlein L, Mayxay M. The use of ultrasensitive quantitative-PCR to assess the impact of primaquine on asymptomatic relapse of Plasmodium vivax infections: a randomized, controlled trial in Lao PDR. Malar J. 2020 Jan 3;19(1):4. doi: 10.1186/s12936-019-3091-5.
- von Seidlein L, Peerawaranun P, Mukaka M, Nosten FH, Nguyen TN, Hien TT, Tripura R, Peto TJ, Pongvongsa T, Phommasone K, Mayxay M, Imwong M, Watson J, Pukrittayakamee S, Day NPJ, Dondorp AM. The probability of a sequential Plasmodium vivax infection following asymptomatic Plasmodium falciparum and P. vivax infections in Myanmar, Vietnam, Cambodia, and Laos. Malar J. 2019 Dec 30;18(1):449. doi: 10.1186/s12936-019-3087-1.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Primaquine | Small molecule | 0.5 mg/kg | — |
| Comparator | Primaquine | Small molecule | 0.75 mg/kg | — |
| Comparator | ARTENIMOL | Small molecule | — | — |
| Comparator | piperaquine | Small molecule | — | — |